SEC Comment Letter 0000000000-24-005835 to Cullinan Therapeutics, Inc. (CGEM) (CIK 0001789972) (CGEM)
Cullinan Therapeutics, Inc. (CGEM) (CIK 0001789972)
Date: May 20, 2024 · CIK: 0001789972 · Accession: 0000000000-24-005835
AI Filing Summary & Sentiment
File numbers found in text: 333-279452
Letter
United States securities and exchange commission logo May 20, 2024 Jacquelyn Sumer General Counsel Cullinan Therapeutics, Inc. One Main Street Suite 1350 Cambridge, MA 02142 Re:Cullinan Therapeutics, Inc. Registration Statement on Form S-3 Filed May 16, 2024 File No. 333-279452 Dear Jacquelyn Sumer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas Daniekski
Show Raw Text
United States securities and exchange commission logo
May 20, 2024
Jacquelyn Sumer
General Counsel
Cullinan Therapeutics, Inc.
One Main Street
Suite 1350
Cambridge, MA 02142
Re:Cullinan Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 16, 2024
File No. 333-279452
Dear Jacquelyn Sumer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Thomas Daniekski